Our Commitment to Endometriosis Diagnostics
Endometriosis is a relatively common, complex, chronic, progressive and intensely painful gynecological condition affecting 10-15% (>70 million) of women between ages 13 – 40 worldwide for which a simple, blood-based precision diagnostic test would significantly improve patient care and its cost to the health system.
Patients with endometriosis present with a variety of symptoms. The most common are chronic pelvic pain and infertility; others include dysuria, dysmenorrhea, and dyspareunia. These symptoms are also signs of other lower abdominal and gynecological diseases such as irritable bowel syndrome, interstitial cystitis or adenomyosis. Consequently, endometriosis is frequently mis-diagnosed resulting in an average time from first onset of symptoms to a definitive diagnosis of more than 10 years. During this time, the disease often spreads to other organs and tissues, significantly increasing symptomatic discomfort, complicating patient care, and increasing the cost of care.
Today, the standard of care diagnostic method is invasive laparoscopic surgery followed by pathologist confirmation. This is expensive, painful/intrusive surgery, and yields variable accuracy (50 – 80%) depending on the skills and experience of the practitioner. Because of this variability, on average, women with endometriosis undergo 3-5 laparoscopic surgeries during their journey with the progressive disease.
A definitive, non-intrusive, blood test for early endometriosis diagnosis would be game changing for patients, clinicians and payers. Laparoscopic excision of the definitively diagnosed disease shortly after it became symptomatic would prevent years of pain, eliminate the spread of the disease to other abdominal organs, improve patients’ quality of life, and reduce substantial and avoidable health system costs.
GenPro is poised to exploit this huge underserved women's health need by applying its novel science and machine learning platform technology to develop and commercialize an immune system epigenetic blood test for early endometriosis diagnosis from a standard whole blood draw. Such a test will rapidly change and improve the standard of female pelvic pain and endometriosis care for general practitioners, community gynecologists as well as the most renowned specialists. The definitive patient care information from this test will provide them key actionable results that they need but presently do not have easy or cost-effective access to. GenPro's initial studies are yielding promising > 85% sensitivity and specificity results.
Further, GenPro is pursuing partnership arrangements with biopharma companies who are developing new drug treatments for endometriosis wherein GenPro discovers a novel immune system epigenetic biomarker (EpiMarker) matched to the drug, and translates the drug-specific EpiMarker into a precision blood test to identify patients who will be responders to the drug.